Dobran Injection (Dobutamine Hydrochloride)

Adult administration

Administer dobutamine as an intravenous infusion at 2.5-10 μg/min per kilogram of body weight. In rare cases, an infusion rate of 40 μg/min per kilogram of body weight may be required to achieve satisfactory effects. The administration rate and treatment duration are adjusted based on the patient's heart rate, exercise-induced changes, blood pressure, urine output, central venous pressure, or pulmonary wedge pressure measurements, and cardiac output. When administering intravenously, dilute in at least 50 mL of a diluent, and the diluent is

This medicine should not be used in patients with certain heart conditions. For example, it is contraindicated in patients with hypertrophic aortic stenosis or those who are allergic to this drug, as well as in patients with problems surrounding the heart tissue. Care should be taken when administering this drug to patients with elevated heart rate or blood pressure, or severe vascular issues, as it may increase heart rate and blood pressure, potentially worsening the condition of hypertensive patients. Attention is also needed for patients with arrhythmias or irregular heartbeats. Because it may cause allergic reactions, individuals sensitive to sulfites, especially asthmatics, should use this medication with caution. Rarely, hypersensitivity reactions such as rash, fever, or difficulty breathing may occur. During administration of this medication, continuous monitoring of blood pressure, heart rate, and ECG is necessary, and appropriate measures should be taken according to the patient's condition. If the patient has low blood volume, it is essential to replenish this before using the medication. There may be interactions when used with other heart-related medications, so consultation with medical personnel is necessary. Care should be taken when combined with MAO inhibitors or beta-blockers. Women who are pregnant or breastfeeding should consult with medical personnel regarding the administration of this medication, as its safety has not been established. Caution is also advised when using this drug in children, as its safety and efficacy has not been adequately confirmed. In elderly patients, starting with a lower dose is recommended, closely monitoring their condition. This drug must be administered only by intravenous infusion, ensuring that the drug does not leak around the injection site. The injection solution should not be mixed with certain solutions, and while color changes may occur before use, this does not affect quality, so it can be used with confidence. In case of overdose, alterations in blood pressure or heart rate may occur; if symptoms arise, administration should be immediately stopped or the dose reduced, and additional treatment is generally not required.

Serious side effects

Shortness of breath (respiratory issues)

Mild side effects

Rash, fever, eosinophilia, bronchospasm, tachycardia, extrasystole, excessive blood pressure increase, angina, precordial warmth, chest discomfort, palpitations, hypotension, abdominal pain, nausea, redness and swelling at the injection site, headache

This medication should be stored in a sealed container to protect it from air and moisture. It is advisable to maintain a storage temperature between 15 and 25 degrees Celsius.

Appearance

A colorless ampule containing a colorless to pale yellow liquid

Package unit

For domestic use - 5 milliliters/ampule [×10 ampules], for export - 5 milliliters/ampule [×10 ampules]